University of Illinois at Chicago
Announcement of an Exempt Purchase
Vendor: University of Wisconsin-Madison dba Waisman Biomanufacturing, Madison, WI
Amount: An estimated $376,861
An estimated start date of 11/7/2018 through 9/29/2022
The University award process may be delayed up to thirty days as this award goes through a state approval process.
First published Friday, November 9, 2018
The University awarded a contract for mesechymal stem cells.
Producing and distributing mesenchymal stem cells to treat eye injuries. The production of stem cells are related to sponsored research and will also be used in clinical trials.
This purchase is exempt from the usual selection processes of the Procurement Code because the procurement expenditure is for performing sponsored research and other sponsored activities under grants and contracts funded by the sponsor or by sources other than State appropriations. (30 ILCS 500 / 1-13(b)(8)) Waisman Biomanufacturing is a specialized cleanroom facility that is specifically designed and constructed to meet requirements for facilities that are involved in the manufacture of cell therapeutics, gene therapeutics, gene therapy vectors, and biologics for phase I/II human clinical trials. The facility's design meets/exceeds FDA guidelines for clinical research purposes. Dr. Djalilian has been awarded a federally-funded grant and this vendor was included in the grant application. The research will improve clinical practice and may bring the University revenue.
For additional information, contact:
The State of Illinois has a policy to encourage prospective vendors to hire
qualified veterans, minorities, females, persons with disabilities and ex-offenders.